The increased iron deposition of the gray matter over the whole brain in chronic migraine: An exploratory quantitative susceptibility mapping study

Zhiye Chen1,2,*, He Zhao3,4,*, Xiaoyan Chen3,*, Mengqi Liu1,5, Xin Li2, Lin Ma5, and Shengyuan Yu3

Abstract

Background: Prior studies identified iron deposition in deep brain nuclei and the periaqueductal gray matter region in chronic migraine, and less is known about the cerebral iron deposition over the whole cerebral gray matter in CM. The aim of this case–control study is to investigate the cerebral iron deposition of gray matter in CM using an advanced quantitative susceptibility mapping.

Methods: A multi-echo gradient echo MR sequence was used to obtain raw quantitative susceptibility mapping data from 12 CM patients and 18 normal controls and the quantitative susceptibility mapping were reconstructed. Three dimensional T1 images were segmented and the gray matter mask was generated to extract the susceptibility value of gray matter over the whole brain. The independent t test and receiver operating characteristic curve Receiver operating characteristics was used to investigate the iron deposition changes in CM patients.

Results: CM presented a higher susceptibility value (1.44 × 10⁻³ ppm) compared with NC group (0.47 × 10⁻³ ppm) (p < 0.0001) over the whole cerebral gray matter. There was no correlation between susceptibility value and the clinical variables including disease duration, Visual Analog Scale (VAS), Migraine Disability Assessment Scale (MIDAS), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), and Montreal Cognitive Assessment (MoCA) scores (p > 0.05). ROC analysis demonstrated the susceptibility had a high diagnostic efficacy (AUC 0.949, sensitivity 77.78% and specificity 100%) in distinguishing CM from NC.

Conclusion: CM patients had increased iron deposition in total cerebral gray matter which could be considered as a potential diagnostic and evaluated imaging biomarker in CM.

Keywords
Chronic migraine, iron deposition, quantitative susceptibility mapping, magnetic resonance imaging, brain

Date Received: 11 November 2021; Revised 25 December 2021; accepted: 29 December 2021

1Department of Radiology, Hainan Hospital of Chinese PLA General Hospital, Sanya, China
2The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
3Department of Neurology, First Medical Center of Chinese PLA General Hospital, Beijing, China
4School of Medicine, Nankai University, Tianjin, China
5Department of Radiology, First Medical Center of Chinese PLA General Hospital, Beijing, China
*Zhiye Chen, He Zhao and Xiaoyan Chen contributed equally to this work.

Corresponding Authors:
Shengyuan Yu and Lin Ma, Department of Neurology, First Medical Center of Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing 100853, China and Department of Radiology, First Medical Center of Chinese PLA General Hospital, Fuxing Road 28, Haidian District, Beijing 100853, China. Email: yusy1963@126.com and cjr.malin@vip.163.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Migraine is a common disabling primary headache disorder worldwide. Chronic migraine (CM) has been defined as headache occurring at least 15 days per month for a period of more than 3 months, and at least 8 days per month with features of migraine according to International Classification of Headache Disorders, 3rd edition (ICHD-III). Approximately 1–2% of population suffered from CM globally, which imposes a significant burden on families and society for migraineurs. Despite the prevalence of this disabling condition, the physiopathological mechanism is still unclear and early diagnosis is difficult. Chronicity of migraine accounts for approximately 2.5% of episodic migraines annually, and its neuromechanism remains unknown.

Cerebral gray matter plays an important role in the pathophysiology of CM, and the previous study demonstrated that gray matter was associated with pain sensitivity, which was common in chronic pain. Advanced functional imaging studies have shown that functional connectivity changed in cortex and deep nuclei in both the interictal and ictal phases of migraine, and further structural imaging studies also indicated significantly abnormal gray matter volumes in migraine. Recently, some studies have shown that CM patients had greater iron accumulation in deep nuclei and periaqueductal gray matter (PAG), suggesting that accurate assessment of cerebral iron deposition may be considered another important research topic for understanding the pathophysiological mechanism of chronic migraine.

Previous studies have assessed iron deposition in deep brain nuclei and PAC using T2, T2* (semi-quantitative assessment), and SWI sequences (visual assessment) in CM patients. However, quantitative analysis of iron deposition was not performed in CM patients. Quantitative susceptibility mapping (QSM) is an advanced MRI technique that quantitatively analyzes the magnetic susceptibility of magnetically sensitive materials, which could be used to quantitatively assess cerebral iron deposition in multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease, and cerebral bleeds. In previous studies, an analysis of the region of interest (ROI) was used to assess cerebral iron deposition, which could not truly reflect cerebral iron deposition at the whole brain level. Therefore, in the current study, a susceptibility analysis of the whole brain gray matter was performed, which would provide more valuable information for understanding the neuromechanism of CM.

The aim of this study is to quantitatively assess iron deposition in whole brain gray matter, compare differences between CM patients and healthy controls, and further investigate the possible role of iron accumulation in chronicity mechanisms.

Materials and methods

Design

Exploratory observational analytic study with case-control design.

Subjects

Twelve CM patients (9 females and 3 males, mean age 40.17 ± 8.47 years) and 18 normal controls (NC, 12 females and 6 males, mean age 40.11 ± 10.98 years) were enrolled from the Neurologic Clinic of Chinese PLA General Hospital. The written informed consents were obtained from all subjects according to the approval of the ethics committee of the local institutional review board.

The included criteria should meet the ICHD-III criteria of chronic migraine without aura, which was listed as follows: (1) CM diagnosis refers to 1.3CM in ICHD-III and without aura; (2) without preventive medication history for migraine in the past 3 months; (3) absence of other subtypes of headache, chronic pain other than headache, severe anxiety or depression, and psychiatric diseases; and (4) absence of alcohol, nicotine, or other substance abuse. The exclusion criteria should meet the following: cranium trauma, cerebral vascular disease, long-standing hypertension, diabetes mellitus, tumor history, brain surgery, and other disorders resulting in cerebral increased iron deposition (Supplementary table 1).

NCs were recruited from the society, and should never have any primary headache disorders or other types of headaches. Two groups had the same exclusion criteria.

All the patients were performed with the Visual Analog Scale (VAS), Migraine Disability Assessment Scale (MIDAS), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), and Montreal Cognitive Assessment (MoCA) evaluation. NCs were performed with HAMA, HAMD, and MoCA evaluation.

MRI acquisition

MR images were obtained by using a conventional eight channel phased-array head coil on a GE 3.0 T MR scanner (DISCOVERY MR750, GE Healthcare, Milwaukee, WI, USA). QSM raw data was acquired by a multi-echo gradient echo T2 weighted sequence with the following parameters: first echo time (TE) = 4.72 ms, the last TE = 22.96 ms, repetition time (TR) = 26.7 ms, flip angle (FA) = 15°, field of view (FOV) = 22 × 22 cm and matrix = 416 × 320, slice thickness = 1.2 mm, slice gap = −0.6 mm, number of averages = 1. Three dimensional T1 gradient echo sequence was performed with the following parameters: TE = 3.0 ms, TR = 7.0 ms, inversion time = 400 ms, FA = 12°, FOV = 25.6 × 25.6 cm and matrix = 256 × 256, slice thickness =
1.0 mm, slice gap = 0.6 mm, number of averages = 1. All MR imaging protocols were performed by the same operator.

**Imaging processing**

The QSM images were reconstructed by STI Suite (V3.0) software (STI.SUITE.MRI@gmail.com). The imaging coregister, normalization, and QSM value extraction were performed with Statistical Parameters Mapping (SPM) (v12.0) software (https://www.fil.ion.ucl.ac.uk/spm/software/).

Figure 1. The quantitative susceptibility mapping (QSM) value of gray matter over the whole brain was extracted according to the above flowchart. (A), raw QSM image; (B), normalized QSM; (C), Gray matter mask; (D), the gray matter mask and normalized QSM.

Figure 2. The extraction of the susceptibility value of the cerebral regions labeled by the automated anatomical labeling (AAL) template (No.1–90).

The image processing steps included as follows: (1) The magnitude images and phase images were imported into the STI software and then automatically generated magnetic susceptibility images (Figure 1(a)); (2) 3D T1 images were coregistered with the magnitude images (TE = 4.72 ms), and then generated the warped T1 images; (3) The individual warped T1 images were normalized with the T1 template (provided by the SPM software), and then The warped T1 images generated the normalized parameters; (4) The normalized parameters were applied with the quantitative susceptibility images, and then
generated the normalized susceptibility images (Figure 1(b)); (5) The warped T1 images of CM and NCs were segmented to gray matter and white matter probability maps, and the all the gray matter probability maps were used to make average gray matter probability and the generated gray matter mask (Figure 1(c)); and (6) The susceptibility value was extracted from the normalized QSM maps based on the gray matter mask (Figure 1(d)) by REST software [V1.8, Forum of resting-state fMRI (restfmri.net)].

The regions of interest (ROI) method based on automated anatomical labeling (AAL) template (Figure 2) was used to extract the magnetic susceptibility value of the regional brain regions and the subcortical gray nuclei using REST software (V1.8).

**Statistical analysis**

The data with normal distribution (Kolmogorov–Smirnov test) was described as mean ± standard deviation. The Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), Montreal Cognitive Assessment (MoCA) score, and susceptibility value were performed with independent sample t test (2 tails, age as covariable). Correlation analysis was applied between susceptibility value and the clinical variables in CM patients. Significant level was set as p value of <0.05. Receiver operating characteristics (ROC) curve was applied to evaluate the diagnostic efficacy of the susceptibility value, and area under the curve (AUC) was recognized reasonable diagnostic valuable with AUC >0.7.

**Results**

This study enrolled 12 CM patients and 18 NCs, and the clinical variables had been listed in the Table 1. HAMA and HAMD presented significant difference between CM and NC (p < 0.05), and MoCA showed no significant difference for two groups (p = 0.07).

**Table 1.** The clinical variables between chronic migraine (CM) and normal controls (NC).

|                  | Gender (M/F) | DD (ys) | HDPM | VAS   | HAMA   | HAMD   | MoCA  | MIDAS |
|------------------|--------------|---------|------|-------|--------|--------|-------|-------|
| **CM**           | 41.71 ± 8.87 | 3/9     | 12.67 ± 9.96 | 24.64 ± 7.62 | 8.08 ± 1.44 | 22.08 ± 10.60 | 17.92 ± 11.37 | 23.75 ± 4.97 | 108.92 ± 57.21 |
| **NC**           | 42.36 ± 11.10 | 6/12 | NA   | NA    | NA     | 11.00 ± 3.24 | 9.00 ± 4.91 | 27.00 ± 2.12 | NA    |
| t value          | 0.19         | 0.01*   | NA   | NA    | NA     | 3.64   | 2.68   | 1.99   | NA    |
| p Value          | 0.85         | 0.91    | NA   | NA    | NA     | 0.00034 | 0.02   | 0.07   | NA    |

*χ2 value. NA, not available; DD, disease duration; HDPM, headache days per month; VAS, Visual Analog Scale; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; MoCA, Montreal Cognitive Assessment; MIDAS, Migraine Disability Assessment Scale.

CM presented a higher susceptibility value (1.44×10^{-3} ppm) compared with the NC group (0.47×10^{-3} ppm) (p < 0.0001) (Figure 3). Although the standard deviation of ages was 10 years in NCs, the coefficient of skewness was calculated as −0.8413 (p = 0.8678), and suggested that age had no significant effect on the results. There was no significant correlation between susceptibility value and the clinical variables including disease duration, headache days per month, VAS, HAMA, HAMD, MoCA, and MIDAS scores (p > 0.05) (Table 2).
Receiver operating characteristics analysis of susceptibility value of CM and NC

The area under curve (AUC) was 0.949 (95% CI 0.879–1.019), and the cut-off value of the susceptibility value was set as 0.908×10^7/C0 with sensitivity 77.78% and specificity 100% in distinguishing CM from NC (Figure 4).

Discussion

Our exploratory cross-sectional study with QSM found that CM had a higher sensitivity score in whole brain gray matter compared to the NC group. There was no correlation between susceptibility value and clinical variables. The ROC analysis showed that QSM had high diagnostic efficacy in discrimination.

The prior studies demonstrated that increased iron deposition in affected brain regions, including PAG and red nuclei, may be related to clinical variables such as the duration of the disease and the frequency of attacks, suggesting that increased infratentorial iron deposition presented in migraine. Another study found increased iron deposition in the globus pallidus in episodic migraine (EM) and was able to distinguish EM from CM, suggesting that increased iron deposition in subcortical nuclei may play a role in the development or pathophysiology of migraine. However, cortical iron deposition in migraine has not been reported previously. Therefore, the current study sought to investigate iron deposition in the whole gray matter.

The current results indicated that CM patients had higher sensitivity values than NC in whole gray matter, suggesting that rich iron deposition was detected in CM. To date, the pathophysiology of migraine mainly included vascular and neural mechanisms. The increased iron deposition in this study reflected not only the vascular mechanism, which could be explained by cerebral venous insufficiency, but also the neural mechanism, which is related to free radical damage, cellular transport of iron, and disruption of iron homeostasis in CM. The causes of increased iron deposition in brain gray matter in CM could include: (1) The transferrin presents in the brain and its receptors, which may contribute to the transfer of iron to cells. Transferrin is much more distributed in the gray matter of the brain than in the white matter. Therefore, the increased iron deposition might be associated with the higher iron metabolism and (2) The free radicals could easily damage the neurons with high iron transferrin levels, and the migraine attacks could lead to hyperoxia episodes and then increase the iron-induced free radical cell damage, which could lead to increased iron deposition.

Previous studies focused on the deep nuclei and PAG to investigate iron deposition. However, in the current study, iron deposition was mainly evaluated from the perspective of the whole brain gray matter, reducing the influence of selection bias without prior hypothesis. The increased iron deposition in the whole brain gray matter could explain the chronicity of migraine, which could be associated with central sensitization, ultimately leading to synaptic plasticity, increased neuronal excitability, and enhanced neuronal response to painful stimuli in the central nervous system. In addition, the high iron content of brain gray matter would...
promote future research focused on altering connectivity between the cortex and subcortical gray nuclei in CM.

Further correlation analysis showed that susceptibility value had no statistically significant relationship with clinical variables assessed at the whole gray matter level to measure iron deposition. However, a prior study demonstrated a correlation between clinical variables and iron deposition when focusing on the gray nuclei area. The difference of these two studies might be related with the brain iron deposition region of interest, which further indicated the iron deposition of whole gray matter might be useful in future studies as an independent imaging biomarker to distinguish CM from NC without 3-month clinical observation. Furthermore, the finding may suggest the different mechanisms of supra-tentorial and subtentorial structure. Structural and functional imaging studies showed differences in thalamic and thalamo-cortical activity in migraine patients both during and between migraine attacks, indicating supratentorial structure might play an independent mechanism in CM development.

In contrast, activation of the descending pain modulation system, including PAG could be response to the repeated pain stimulation.

Figure 4 further showed that susceptibility value could discriminate CM patients with a sensitivity of 77.78% and a specificity of 100% (AUC = 0.949), which could be considered as an optimal imaging biomarker for the diagnosis of CM. Previously, conventional, functional, and structural MRI had been used to understand the neuromechanism of CM and had limited clinical practice. However, quantitative assessment of iron deposition by QSM could be conveniently performed from a clinical perspective. In our study, iron deposition was re-evaluated in the following ways: (1) quantitative evaluation was performed by QSM method, while conventional iron deposition was evaluated semi-quantitatively with T2*, SWI, T2, and T2/ sequence; (2) iron deposition was measured in the whole brain gray matter, while conventional evaluation was limited to subcortical gray nuclei and PAG; and (3) it was an automatic
measurement of iron deposition without subjective bias, whereas the conventional measurement was performed using the ROI method with manual drawing.

In the current study, Figure 6 suggested the altered pattern of the iron deposition presented as follows: (1) All the positive brain regions with altered iron deposition all located in the cortex, while the gray nuclei of the basal ganglia all presented no significant altered iron deposition; Compared with episodic migraine and normal controls, the morphological changes mainly locate the in the cerebral region might be associated the cortical region involved in the pain circuitry,43,44 and this morphological change pattern might be consistent with the altered iron deposition pattern in the current study, which should be further investigated. (2) The brain regions with the increased iron deposition mainly located in the bilateral frontal and parietal lobe and left middle occipital gyrus (22 brain regions), and the decreased iron deposition located in the inferior temporal gyrus (1 brain region). The increased iron deposition of the frontal and parietal gyri might be contributed to the reduced functional connectivity in the sensorimotor areas and cortex in CM patients45 and disrupted pain processing.46 However, the decreased iron deposition of the left inferior temporal gyrus might be related with vascular mechanism,33 and the brain MR perfusion investigation should further be performed in CM patients in the future (Cerebral perfusion changes in migraineurs: a voxelwise comparison of interictal dynamic susceptibility contrast MRI measurements).

Limitations of this study include: (1) the samples were relatively small, and therefore the results could only reflect the neuromechanism of CM to a certain extent; (2) other types of migraine should be investigated in the future study to better understand the neuromechanism of migraine; and (3) this study was a cross-sectional observation and could not directly infer the causal relationship in shifting the phenotype from episodic to chronic migraine. Therefore, longitudinal studies and assessment of response to treatment such as onabotulinumtoxin A47 should be conducted in the future.

Conclusions

In conclusion, this study used the QSM technique to show the increased iron deposition in whole cerebral gray matter in CM. The susceptibility value of whole cerebral gray matter could be considered as a highly sensitive imaging biomarker for the diagnosis of CM, and QSM technique would be an optimal and simple tool for routine clinical practice in the diagnosis and therapeutic evaluation of CM.

Author contributions

Zhiye Chen conceived and wrote the paper. Xiaoyan Chen collected clinical data. He Zhao and Xin Li wrote part of the paper. Mengqi Liu collected imaging data. Zhiye Chen analyzed the data. Lin Ma and Shengyuan Yu revised the paper.

Declaration of conflicting interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Ethic statement**

This study was carried out in accordance with the recommendations of the Ethics Committee of Chinese PLA General Hospital with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committee of Chinese PLA General Hospital (S2015-085–01).

**ORCID iD**

Shengyuan Yu [https://orcid.org/0000-0001-8933-088X](https://orcid.org/0000-0001-8933-088X)

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Disease GBD. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; 392: 1789–1858.

2. GBDN. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2019; 18: 459–480.

3. Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullivan MJM, Kaufman J, Collins G, Dai H, Bragazzi NL, Kolahi AA. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. *Pain* 2022; 163(2): e293–e309.

4. Headache classification committee of the international headache society (IHS) the international classification of headache disorders, 3rd edition. *Cephalalgia* 2018; 38:1–211

5. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. *Neurology Clin* 2019; 37: 631–649.

6. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. *Neurology* 2009; 72: S3–S7.

7. DeSouza DD, Cowan RP. Insights into chronic migraine pathophysiology - what measures of gray matter reveal. *Cephalalgia* 2020; 40: 1136–1137.

8. Ruscheweyh R, Wersching H, Kugel H, Sundermann B, Teuber A. Gray matter correlates of pressure pain thresholds and self-rated pain sensitivity: a voxel-based morphometry study. *Pain* 2018; 159: 1359–1365.

9. Coppola G, Di Renzo A, Tinelli E, Di Lorenzo C, Di Lorenzo G, Parisi V, Serrao M, Schoenen J, Pierelli F. Thalamo-cortical network activity during spontaneous migraine attacks. *Neurology* 2016; 87: 2154–2160.

10. Hougaard A, Amin FM, Larsson HB, Rostrup E, Ashina M. Increased intrinsic brain connectivity between pons and somatosensory cortex during attacks of migraine with aura. *Hum Brain Mapp* 2017; 38: 2635–2642.

11. Hodkinson DJ, Wilcox SL, Veggeberg R, Noseda R, Burstein R, Borsook D, Becerra L. Increased amplitude of thalamocortical low-frequency oscillations in patients with migraine. *J Neurosci* 2016; 36: 8026–8036.

12. Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. *Brain* 2016; 139: 1987–1993.

13. Amin FM, Hougaard A, Magon S, Asghar MS, Ahmad NN, Rostrup E, Sprenger T, Ashina M. Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study. *Neurology* 2016; 86: 180–187.

14. Ke J, Yu Y, Zhang X, Su Y, Wang X, Hu S, Dai H, Hu C, Zhao H, Dai L. Functional alterations in the posterior insula and cerebellum in migraine without aura: a resting-state MRI study. *Front Behav Neurosci* 2020; 14: 567588.

15. Neeb L, Bastian K, Villringer K, Israel H, Reuter U, Fiebach JB. Structural gray matter alterations in chronic migraine: implications for a progressive disease? *Headache* 2017; 57: 400–416.

16. Chen Z, Chen X, Liu M, Liu S, Max L, Yu S. Volume expansion of periaqueductal gray in episodic migraine: a pilot MRI structural imaging study. *J Headache Pain* 2017; 18: 83.

17. Bilgiç B, Kocaman G, Arslan AB, Noyan H, Sherifov R, Alkan A, Asil T, Parman Y, Baykan B. Volumetric differences suggest involvement of cerebellum and brainstem in chronic migraine. *Cephalalgia* 2016; 36: 301–308.

18. Coppola G, Petolicchio B, Di Renzo A, Tinelli E, Di Lorenzo C, Parisi V, Serrao M, Calisti V, Tardioli S, Cartoccì G, Ambrosini A, Caramia F, Di Pioero V, Pierelli F. Cerebral gray matter volume in patients with chronic migraine: correlations with clinical features. *J Headache Pain* 2017; 18: 115.

19. García-Azorín D, Guerrero Á L, Rodriguez M, Aja-Fernández S, de Luis-García R. Gray matter structural alterations in chronic and episodic migraine: a morphometric magnetic resonance imaging study. *Pain Medicine* 2020; 21: 2997–3011.

20. Kruit MC, Overbosch J, van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. *Cephalalgia* 2018; 38:301–308.

21. Tepper SJ, Lowe MJ, Beall E, Phillips MD, Liu K, Stillman MJ, Horvat M, Jones SE. Iron deposition in pain-regulatory nuclei in episodic migraine and chronic daily headache by MRI. *Headache* 2012; 52: 236–243.

22. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? *Headache* 2001; 41: 629–637.

23. Dominguez C, López A, Ramos-Cabrero P, Vieites-Prado A, Pérez-Mato M, Villalba C, Sobrino T, Rodriguez-Osorio X, Campos F, Castillo J, Leira R. Iron deposition in periaqueductal
gray matter as a potential biomarker for chronic migraine. *Neurology* 2019; 92: e1076–e1085.

24. Palm-Meinders IH, Kappen H, Terwindt GM, Launer LJ, van Buchem MA, Ferrari MD, Kruit MC. Iron in deep brain nuclei in migraine? *CAMERA* follow-up MRI findings. *Cephalalgia* 2017; 37: 795–800.

25. Langkammer C, Schweser F, Krebs N, Deistung A, Goessler W, Scheurer E, Sommer K, Reishofer G, Yen K, Fazekas F, Ropele S, Reichenbach JR. Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study. *Neuroimage* 2012; 62: 1593–1599.

26. Gillen KM, Mubarak M, Park C, Ponath G, Zhang S, Dimov A, Levine-Ritterman M, Toro S, Huang W, Amici S, Kaunzner UW, Gauthier SA, Guerra-de-Arellano M, Wang Y, Nguyen TD, Pitt D. QSM is an imaging biomarker for chronic glial activation in multiple sclerosis lesions. *Ann Clin Transl Neurol* 2021; 8: 877–886.

27. Chen J, Cai T, Li Y, Chi J, Rong S, Wang L, Zhang Y. Different iron deposition patterns in Parkinson’s disease subtypes: a quantitative susceptibility mapping study. *Quant Imaging Med Surg* 2020; 10: 2168–2176.

28. Wang C, Foxley S, Ansgore O, Bangerter-Christensen S, Chiew M, Leonte A, Menke RA, Mollink J, Pallebage-Gamarallage M, Turner MR, Miller KL, Tendler BC. Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T applied to amyotrophic lateral sclerosis. *Neuroimage* 2020; 222: 112716.

29. Bhattachar A, Chen Z, Ward PGD, Talman P, Mathers S, Phan TG, Chapman C, Howe J, Lee S, Lie Y, Egan GF, Chua P. Serial assessment of iron in the motor cortex in limb-onset amyotrophic lateral sclerosis using quantitative susceptibility mapping. *Quant Imaging Med Surg* 2020; 10: 1465–1476.

30. Sun H, Klahr AC, Kate M, Gioia LC, Emery DJ, Butcher KS, Wilman AH. Quantitative susceptibility mapping for following intracranial hemorrhage. *Radiology* 2018; 288: 830–839.

31. Schellingerhout D, Jacobsen M, Le Roux L, Johnson J, Babadandayuthapani V, Hwang KP, Hazle J, Schomer D, Cody D. The calcium versus hemorrhage trial: developing diagnostic criteria for chronic intracranial susceptibility lesions using single-energy computed tomography, dual-energy computed tomography, and quantitative susceptibility mapping. *Invest Radiol* 2021; 56: 385–393.

32. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage* 2002; 15: 273–289.

33. Jagannath VA, Pucci E, Asokan GV, Robak EW. Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis. *Cochrane Database Syst Rev* 2019; 5: CD009903.

34. Pietrobon D, Moskowitz MA. Pathophysiology of migraine. *Annu Rev Physiol* 2013; 75: 365–391.

35. Belaidi AA, Bush AI. Iron neurochemistry in Alzheimer’s disease and Parkinson’s disease: targets for therapeutics. *J Neurochem* 2016; 139(Suppl 1): 179–197.

36. Zarruk JG, Berard JL, Passos dos Santos R, Kroner A, Lee J, Arosio P, David S. Expression of iron homeostasis proteins in the spinal cord in experimental autoimmune encephalomyelitis and their implications for iron accumulation. *Neurobiol Dis* 2015; 81: 93–107.

37. Morris CM, Candy JM, Omar S, Bloxham CA, Edwardson JA. Transferrin receptors in the parkinsonian midbrain. *Neuropathol Appl Neurobiol* 1994; 20: 468–472.

38. Adams JD Jr., Oduzne IN. Oxygen free radicals and Parkinson’s disease. *Free Radic Biol Med* 1991; 10: 161–169.

39. Cao Y, Welch KM, Aurora S, Vikingstad EM. Functional MRI-BOLD of visually triggered headache in patients with migraine. *Arch Neurol* 1999; 56: 548–554.

40. Burststein R. Deconstructing migraine headache into peripheral and central sensitization. *Pain* 2001; 89: 107–110.

41. Coppola G, Di Renzo A, Tinelli E, Lepre C, Di Lorenzo G, Sapeccia M, Parisi V, Serrao M, Colonnese C, Schoenen J, Pierelli F. Thalamo-cortical network activity between migraine attacks: Insights from MRI-based microstructural and functional resting-state network correlation analysis. *J Headache Pain* 2016; 17: 100.

42. Schwedt TJ, Schlaggar BL, Mar S, Nolan T, Coalson RS, Nardos B, Benzingler T, Larson-Prior LJ. Atypical resting-state functional connectivity of affective pain regions in chronic migraine. *Headache* 2013; 53: 737–751.

43. Valfrè W, Rainero I, Bergui M, Pinessi L. Voxel-based morphometry reveals gray matter abnormalities in migraine. *Headache* 2008; 48: 109–117.

44. Lai KL, Niddam DM, Fuh JL, Chen WT, Wu JC, Wang SJ. Cortical morphological changes in chronic migraine in a Taiwanese cohort: Surface- and voxel-based analyses. *Cephalalgia* 2020; 40: 575–585.

45. Qin Z, Su J, He XW, Ban S, Zhu Q, Cui Y, Zhang J, Hu Y, Liu YS, Zhao R, Qiao Y, Li J, Liu JR, Du X. Disrupted functional connectivity between sub-regions in the sensorimotor areas and cortex in migraine without aura. *J Headache Pain* 2020; 21: 47.

46. García-Azorín D, Guererro À L, Aja-Fernández S, Rodríguez M, de Luis-García R. Structural connectivity alterations in chronic and episodic migraine: A diffusion magnetic resonance imaging connectomics study. *Cephalalgia* 2020; 40: 367–383.

47. Domínguez Vivero C, Leira Y, Saavedra Piñeiro M, Rodríguez-Osorio X, Ramos-Cabrер P, Villalba Martin C, Sobrino T, Campos F, Castillo J, Leira R. Iron deposits in periaqueductal gray matter are associated with poor response to onabotulinumtoxina in chronic migraine. *Toxins (Basel)* 2020; 12.